The investigation centers on a pair of damaging reports published in June 2026. On June 8, Hunterbrook alleged that the company’s profitability stems from systemic understaffing and the manipulation of quality metrics, claiming these cost-cutting measures directly compromised patient safety. The stock responded immediately, sliding $13.88 to close at $156.42.

Pressure intensified on June 11 when Muddy Waters Research leveled accusations of potential Medicare and Medicaid fraud. The report detailed a scheme involving the use of "rented" nursing facility administrators, a practice that may violate the False Claims Act. Following this disclosure, Ensign shares fell another 2.98% to $147.13. Investors seeking to participate in the potential class action are advised to contact Danielle Peyton at Pomerantz LLP.